Absci
Absci's revenue fell 38.2% to $3 million in fiscal 2025. Its operating margin was −4,297.0%, down from −2,401.6% a year earlier. Free cash flow was −$94 million. The diluted share count rose 24.1%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on capital is after-tax operating income as a share of the money invested in the business: debt plus equity, minus cash. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
What Absci does
Absci is a drug developer that has not yet sold a product. It uses artificial intelligence models to design antibody medicines and then tests them in its own lab. It says it focuses on targets that are poorly explored, where medical need is high and competition is low.
Its main drug candidate, ABS-201, is an antibody against the prolactin receptor. It is being tested in an early-stage trial for pattern hair loss, and the company plans a mid-stage trial for endometriosis, a chronic condition of the reproductive system. Absci also decided to look for a partner for another candidate, ABS-101, instead of taking it through late-stage development itself.
Absci does not expect revenue from selling its own drugs unless a candidate completes clinical development and wins regulatory approval. Its clinical work may involve partners, and it competes with other companies that use technology to find and design drugs.
Its biggest risks, as it describes them
- It has a short operating history and has lost money since it began.
- It does not expect product sales unless a drug candidate is approved, and all of them are still in testing.
- Clinical trials may be delayed, fail, or give early results that do not hold up.
- FDA may not accept data from its trials run outside the United States, including in Australia.
- Other companies are building competing AI drug design technology.
Income statement
Absci lost money in fiscal 2025: a net loss of $115 million.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 253 | 60 | 72 | 112 | 144 |
| Debt incl. finance leases | 10 | 14 | 9 | 4 | 1 |
| Net debt (negative means net cash) | −243 | −46 | −64 | −108 | −143 |
| Net debt to EBITDA | — | — | — | — | — |
| Debt to equity | 0.0x | 0.1x | 0.1x | 0.0x | 0.0x |
| Interest coverage | −21.9x | −109.8x | −114.4x | −192.7x | −575.7x |
| Current ratio | 8.1x | 6.2x | 4.1x | 4.7x | 6.6x |
| Quick ratio | 8.1x | 6.2x | 4.1x | 4.7x | 6.6x |
Cash flow
Projections
Project Absci's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
Insider trades
Over the 12 months between November 14, 2025 and November 13, 2026, 4 insiders bought $933,174 of Absci shares on the open market, and 2 insiders sold $132,328.
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Jun 30, 2026 | Mary T SzelaDirector | Bought | 12,900 | $11.54 | $148,866 | Form 4 |
| May 13, 2026 | Menelas N PangalosDirector | Bought | 37,453 | $5.36 | $200,748 | Form 4 |
| Mar 12, 2026 | Andreas BuschChief Innovation Officer | Bought | 100,000 | $2.29 | $229,000 | Form 4 |
| Feb 27, 2026 | Menelas N PangalosDirector | Bought | 75,095 | $2.74 | $205,760 | Form 4 |
| Feb 2, 2026 | Sean McClainChief Executive Officer, Director | Sold | 26,761 | $2.99 | $80,015 | Form 4 |
| Feb 2, 2026 | Zachariah JonassonCFO / Cbo | Sold | 17,496 | $2.99 | $52,313 | Form 4 |
| Dec 5, 2025 | Houten Frans VanDirector | Bought | 40,000 | $3.72 | $148,800 | Form 4 |
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | 2 of 8 | 4 of 8 | 3 of 8 |
| Rule of 40 | −1,145.9% | −1,626.5% | −3,396.5% |
| Altman Z'' | −2.42 | −2.52 | −1.90 |
| Accruals ratio | −17.1% | −14.2% | −10.3% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Fail | Fail |
| Cash from operations is positive | Fail | Fail | Fail |
| Return on assets rose | Fail | Fail | Fail |
| Cash from operations exceeds net income | Pass | Pass | Pass |
| Debt fell relative to assets | Fail | Pass | Pass |
| Current ratio rose | Fail | Pass | Pass |
| Share count didn't rise | Fail | Fail | Fail |
| Gross margin rose | — | — | — |
| Revenue rose relative to assets | Pass | Pass | Fail |
| F-score | 2 of 8 | 4 of 8 | 3 of 8 |
Compare
Put Absci side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Absci | FY25 | −38.2% | −4,297.0% | −3,358.3% | −162.8% | — | 3 | |
| CRISPR Therapeutics | FY25 | −90.6% | −18,933.7% | −9,855.5% | — | — | — | Compare |
| CG Oncology | FY25 | 254.7% | −4,722.1% | −3,279.2% | — | — | 2 | Compare |
| Prime Medicine | FY25 | 55.3% | −4,498.1% | −3,607.4% | — | — | — | Compare |
| Celldex Therapeutics | FY25 | −78.0% | −18,599.8% | −13,829.1% | — | — | — | Compare |
6 years of figures
| Fiscal year | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|
| Income statement | ||||||
| Revenue | 5 | 5 | 6 | 6 | 4 | 3 |
| Revenue growth | — | 0.0% | 20.2% | −0.5% | −20.7% | −38.2% |
| Gross profit | — | — | — | — | — | — |
| Research and development | 11 | 45 | 59 | 48 | 64 | 81 |
| Operating income | −13 | −75 | −107 | −116 | −109 | −120 |
| Net income | −14 | −101 | −105 | −111 | −103 | −115 |
| Diluted EPS (US$) | −3.19 | −2.08 | −1.15 | −1.20 | −0.94 | −0.84 |
| Diluted shares (millions) | 16 | 50 | 91 | 92 | 110 | 137 |
| Cash flow | ||||||
| Cash from operations | −11 | −61 | −81 | −65 | −72 | −93 |
| Capital expenditure | 2 | 38 | 16 | 1 | 0 | 1 |
| Free cash flow | −13 | −99 | −98 | −66 | −73 | −94 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 | 0 |
| Acquisitions | 0 | 28 | 8 | 0 | 0 | 0 |
| Stock-based compensation | 0 | 11 | 12 | 11 | 20 | 18 |
| Balance sheet at fiscal year end | ||||||
| Cash and short-term investments | 70 | 253 | 60 | 72 | 112 | 144 |
| Debt incl. finance leases | 9 | 10 | 14 | 9 | 4 | 1 |
| Total assets | 89 | 426 | 321 | 217 | 214 | 216 |
| Total liabilities | 22 | 60 | 47 | 41 | 34 | 27 |
| Shareholders' equity | −89 | 366 | 274 | 176 | 179 | 189 |
| Margins and ratios | ||||||
| Gross margin | — | — | — | — | — | — |
| Operating margin | −278.3% | −1,573.4% | −1,857.5% | −2,020.2% | −2,401.6% | −4,297.0% |
| Net margin | −300.3% | −2,111.2% | −1,825.4% | −1,933.7% | −2,274.1% | −4,113.7% |
| Free cash flow margin | −275.1% | −2,062.8% | −1,696.8% | −1,145.4% | −1,605.8% | −3,358.3% |
| Rule of 40 (growth + FCF margin) | — | −2,062.8% | −1,676.6% | −1,145.9% | −1,626.5% | −3,396.5% |
| Return on capital | — | — | −48.0% | −53.5% | −93.9% | −162.8% |
| Return on equity | — | −73.0% | −32.8% | −49.1% | −58.0% | −62.5% |
| Return on assets | — | −39.2% | −28.1% | −41.1% | −47.9% | −53.6% |
| Net debt to EBITDA | — | — | — | — | — | — |